Periodontal Disease – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：59頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Periodontal Disease – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Periodontal Disease - Pipeline Review, H2 2012', provides an overview of the Periodontal Disease therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontal Disease. 'Periodontal Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Periodontal Disease.
- A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Periodontal Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Periodontal Disease pipeline depth and focus of Periodontal Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Periodontal Disease - Pipeline Review, H2 2012', provides an overview of the Periodontal Disease therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontal Disease. 'Periodontal Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Periodontal Disease.
- A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Periodontal Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Periodontal Disease pipeline depth and focus of Periodontal Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Periodontal Disease Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Periodontal Disease 8
Periodontal Disease Therapeutics under Development by Companies 10
Periodontal Disease Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Periodontal Disease Therapeutics – Products under Development by Companies 17
Periodontal Disease Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Periodontal Disease Therapeutics Development 19
Enzo Biochem, Inc. 19
IMAGENETIX, INC 20
Kaken Pharmaceutical Co.,Ltd. 21
CSL Limited 22
Yuhan Corporation 23
Biomedical Development Corporation. 24
Periodontal Disease – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
POD CRC-OHS - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
1-Tetradecanol Complex - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
KCB-1D - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Enzo-D58 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Tetracycline + Metronidazole + Amoxicillin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Metronidazole + Amoxicillin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tetracycline - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Curcuminoids - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Iocide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Iocide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Omega 3 PUFA + Aspirin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Metronidazole - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Camella Sinensis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PerioPatch - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cell Sheet Pellets + Cell Sheet Fragment - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Aroeira - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Green Propolis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
YH14642 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Periodontal Disease Therapeutics – Drug Profile Updates 51
Periodontal Disease Therapeutics - Dormant Products 52
Periodontal Disease – Product Development Milestones 54
Featured News & Press Releases 54
Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 54
Aug 12, 2009: Imagenetix Announces Publication Of Results From 1-TDC Boston University Periodontal Study In The Journal Of Periodontology 54
Jun 01, 2007: Periodontal Study On Imagenetix Compound 1-TDC Published In Journal Of Periodontology 54
Dec 11, 2006: Imagenetix Receives FDA Clearance To Begin Pre-IND Safety Studies On Anti-Inflammatory Compound 55
Jun 01, 2006: Imagenetix Announces Positive Safety Studies On Anti-Inflammatory Compound, 1-TDC 56
May 22, 2006: CombinatoRx Reports Second Positive Phase 2 Study with CRx-102 56
May 08, 2006: Imagenetix Announces 1-Tetradecanol Complex Acts To Inhibit Bacteria And Enzymes Associated With Oral Disease, Sepsis And Inflammation 56
Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products Under Development for Periodontal Disease, H2 2012 8
Products under Development for Periodontal Disease – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Enzo Biochem, Inc., H2 2012 19
IMAGENETIX, INC, H2 2012 20
Kaken Pharmaceutical Co.,Ltd., H2 2012 21
CSL Limited, H2 2012 22
Yuhan Corporation, H2 2012 23
Biomedical Development Corporation., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Periodontal Disease Therapeutics – Drug Profile Updates 51
Periodontal Disease Therapeutics – Dormant Products 52
Periodontal Disease Therapeutics – Dormant Products (Contd..1) 53
List of Figures
Number of Products under Development for Periodontal Disease, H2 2012 8
Products under Development for Periodontal Disease – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Periodontal Disease Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Periodontal Disease 8
Periodontal Disease Therapeutics under Development by Companies 10
Periodontal Disease Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Periodontal Disease Therapeutics – Products under Development by Companies 17
Periodontal Disease Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Periodontal Disease Therapeutics Development 19
Enzo Biochem, Inc. 19
IMAGENETIX, INC 20
Kaken Pharmaceutical Co.,Ltd. 21
CSL Limited 22
Yuhan Corporation 23
Biomedical Development Corporation. 24
Periodontal Disease – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
POD CRC-OHS - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
1-Tetradecanol Complex - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
KCB-1D - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Enzo-D58 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Tetracycline + Metronidazole + Amoxicillin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Metronidazole + Amoxicillin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tetracycline - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Curcuminoids - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Iocide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Iocide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Omega 3 PUFA + Aspirin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Metronidazole - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Camella Sinensis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PerioPatch - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cell Sheet Pellets + Cell Sheet Fragment - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Aroeira - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Green Propolis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
YH14642 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Periodontal Disease Therapeutics – Drug Profile Updates 51
Periodontal Disease Therapeutics - Dormant Products 52
Periodontal Disease – Product Development Milestones 54
Featured News & Press Releases 54
Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 54
Aug 12, 2009: Imagenetix Announces Publication Of Results From 1-TDC Boston University Periodontal Study In The Journal Of Periodontology 54
Jun 01, 2007: Periodontal Study On Imagenetix Compound 1-TDC Published In Journal Of Periodontology 54
Dec 11, 2006: Imagenetix Receives FDA Clearance To Begin Pre-IND Safety Studies On Anti-Inflammatory Compound 55
Jun 01, 2006: Imagenetix Announces Positive Safety Studies On Anti-Inflammatory Compound, 1-TDC 56
May 22, 2006: CombinatoRx Reports Second Positive Phase 2 Study with CRx-102 56
May 08, 2006: Imagenetix Announces 1-Tetradecanol Complex Acts To Inhibit Bacteria And Enzymes Associated With Oral Disease, Sepsis And Inflammation 56
Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products Under Development for Periodontal Disease, H2 2012 8
Products under Development for Periodontal Disease – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Enzo Biochem, Inc., H2 2012 19
IMAGENETIX, INC, H2 2012 20
Kaken Pharmaceutical Co.,Ltd., H2 2012 21
CSL Limited, H2 2012 22
Yuhan Corporation, H2 2012 23
Biomedical Development Corporation., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Periodontal Disease Therapeutics – Drug Profile Updates 51
Periodontal Disease Therapeutics – Dormant Products 52
Periodontal Disease Therapeutics – Dormant Products (Contd..1) 53
List of Figures
Number of Products under Development for Periodontal Disease, H2 2012 8
Products under Development for Periodontal Disease – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30
